z-logo
HomeZAIABlog
open-access-imgOpen Access
An Assessment of Linezolid Utilization in Selected Canadian Provinces
Author(s) -
Sandra A N Walker,
Linda Dresser,
Debbie Becker,
Alissa Scalera
Publication year - 2006
Publication title -
canadian journal of infectious diseases and medical microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.634
H-Index - 38
eISSN - 1918-1493
pISSN - 1712-9532
DOI - 10.1155/2006/818535
Subject(s) - linezolid , medicine , enterococcus faecium , daptomycin , bacteremia , antibiotics , vancomycin , staphylococcus aureus , intensive care medicine , emergency medicine , microbiology and biotechnology , biology , bacteria , genetics
Linezolid is approved for the treatment of designated infections caused by methicillin-resistant and -susceptible Staphylococcus aureus and vancomycin-resistant Enterococcus faecium.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

AboutCareersPublisher PartnersContact UsGet Organisational Trial or Quote

Learn

FAQsBlogTerms of UsePrivacy Policy

Download the Zendy App

Get it on
Google Play
Download on the
App Store

Discover

Explore

Copyright Knowledge E © 2026. All Rights Reserved.